Author

Nathan Wlodarchak

Veterans Health AdministrationORCID 0000-0001-8549-4369Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Nathan Wlodarchak1 paper · University of Wisconsin–Madison

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1 Organism:zebrafish· 1

Frequent Co-Authors

Jeff Beczkiewicz· 2 shared Adam Schaenzer· 1 shared Anthony GitteriD· 1 shared Avene Colgan· 1 shared Bill Zuercher· 1 shared Dave Drewry· 1 shared Francesco Capponi· 1 shared Gabriele CorsoiD· 1 shared

Activity by Year

2017-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Jeff Beczkiewicz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivPreprintJul 6, 2026

BoltzMol-1: Towards Reliable Virtual Screening for Fast and Cost-Effective Hit Discovery

Noah Getz, Geoffrey Smith, Avene Colgan…·Saro Passaro

BoltzMol-1 identifies chemically tractable binders for diverse targets with limited experimental resources using model-driven ranking and physicochemical filtering.

DOI 10.64898/2026.07.04.736485

deep learningdrug response / drug discovery

𝕏 PostBluesky

MicrobiologybioRxivPreprintSep 20, 2018

Comparative analysis of PknB inhibitors for reactivity and toxicity

Nathan Wlodarchak, Jeff Beczkiewicz, Steven Seitz…·Rob Striker

This study evaluates the reactivity and toxicity of a PknB inhibitor, YH-8, finding high reactivity with thiolating agents, toxicity in zebrafish, and limited activity against non-tubercular mycobacteria.

DOI 10.1101/423061

zebrafishexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintOct 7, 2017

Repurposed kinase inhibitors and β-lactams as a novel therapy for antibiotic resistant bacteria

Nathan Wlodarchak, Nathan Teachout, Rebecca Procknow…·Rob Striker

This study identifies kinase inhibitors that can be repurposed to combat antibiotic-resistant bacteria and shows they synergize with beta-lactams to enhance antimicrobial efficacy.

DOI 10.1101/199422

proteomicsdeep learning

𝕏 PostBluesky